Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Intrexon Corporation (NYSE: XON) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Intrexon Corporation (NYSE: XON) concerning whether a series of statements by Intrexon Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On April 21, 2016, a report was published alleging that Intrexon technology has recently been questioned by officials from the World Health Organization, the Centers for Disease Control and Prevention, and the National Institutes of Health. The report also alleged that Intrexon overstated revenues by 50% through transactions with related parties; Intrexon’s technology platform is an overhyped, undifferentiated collection of commodity and failed products; and Intrexon is the Theranos of the public markets.

Following this news, NYSE: XON shares dropped more than 26% on April 21, 2016.

Based in Germantown, Maryland, and founded in 1998 Intrexon Corporation operates in the synthetic biology field in the United States.

If you purchased shares of Intrexon Corporation (NYSE: XON) on or before April 21, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185